Latest FOLFOX Stories
THOUSAND OAKS, Calif., Feb.
LUGANO, Switzerland and COPENHAGEN, Denmark, February 5, 2015 /PRNewswire/ -- - Elsiglutide is a GLP-2 receptor agonist with potential as a first-ever therapy to help cancer
Exploratory Analysis of Phase 2 Trial Shows Earlier and Sustained Responses in Patients Treated With Vectibix Versus Bevacizumab THOUSAND OAKS, Calif., Jan.
Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer THOUSAND
BETHLEHEM, Pa., March 20, 2014 /PRNewswire/ -- Saladax Biomedical, Inc.
Adding the drug cetuximab to a regimen of drugs used for the treatment of patients following surgery for stage III colon cancer did not result in improved disease-free survival.
QUEBEC CITY, July 27, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:Â AEZ) (the "Company") today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.
- Emitting flashes of light; glittering.